MC2 Therapeutics Entered into an Agreement with Huadong to Develop and Commercialize Wynzora Cream in Greater China
Shots:
- MC2 will receive $16M in up front and regulatory milestones & is also eligible to receive an additional ~$36M upon achievement of sales milestones along with royalties
- Huadong to get an exclusive right in Greater China (mainland China, Hong Kong, Macau, and Taiwan) to develop and commercialize MC2’s Wynzora Cream for the treatment of plaque psoriasis. The agreement focuses on advancing the clinical development of Wynzora in Greater China to benefit patients with psoriasis using Huadong’s clinical, regulatory, and commercial capabilities
- Wynzora, a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of PsO incl. scalp psoriasis in adults
Ref: MC2 Therapeutics | Image: MC2 Therapeutics
Related News:- MC2 Therapeutics Wynzora Cream Receives the US FDA's Approval to Treat Plaque Psoriasis in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
